Vaccines:
Indications for VAQTA:
Hepatitis A immunization.
Adult Dosage:
≥19 yrs: 1mL IM at elected date and booster dose (1mL IM) 6–18 months later.
Children Dosage:
<12 months: not recommended. 1–18 yrs: 0.5mL IM at elected date and booster dose (0.5mL IM) 6–18 months later.
VAQTA Warnings/Precautions:
Have epinephrine (1:1000) available. Latex allergy. Inject into deltoid muscle, preferably at least 2 weeks before expected exposure. If given with immune globulin, use separate syringe and different site. Fever. Malignancies. Immunocompromised (may have suboptimal response). Bleeding disorders. Pregnancy (Cat.C). Nursing mothers.
VAQTA Interactions:
Immunosuppressives may reduce efficacy. Concomitant vaccines, immune globulins: see literature.
Adverse Reactions:
Injection site reactions (esp. pain, tenderness), headache, fever, GI upset, myalgia, abdominal pain, rash, pharyngitis and other upper respiratory tract effects.
How Supplied:
Prefilled syringes (0.5mL, 1mL)—1, 5; Single-dose vials (0.5mL)—1, 10; Single-dose vials (1mL)—1, 5, 10
